**FOI Ref: 6192**

**Category(ies): Clinical - Drugs**

**Subject: Dermatology Biologic Drugs**

**Date Received: 19/01/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| Could you please provide the numbers of patients treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:   * Adalimumab - Humira * Adalimumab Biosimilar * Apremilast * Bimekizumab * Brodalumab * Certolizumab * Dimethyl fumarate * Etanercept - Enbrel * Etanercept Biosimilar * Guselkumab * Infliximab - Remicade * Infliximab Biosimilar * Ixekizumab * Risankizumab * Secukinumab * Tildrakizumab * Ustekinumab | |  |  | | --- | --- | | Name of Biologic Drug | Number of patients treated in last 3 months | | Adalimumab - Humira | N/A | | Adalimumab Biosimilar | 101 | | Apremilast | 0 | | Bimekizumab | 0 | | Brodalumab | 6 | | Certolizumab | 9 | | Dimethyl fumarate | 0 | | Etanercept - Enbrel | 0 | | Etanercept Biosimilar | 0 | | Guselkumab | 105 | | Infliximab - Remicade | 0 | | Infliximab Biosimilar | 0 | | Ixekizumab | 16 | | Risankizumab | 21 | | Secukinumab | 86 | | Tildrakizumab | 0 | | Ustekinumab | 115 | |